KINAXO Announces Agreement with Johnson & Johnson
Pharmaceutical Research & Development
Martinsried, Germany, January 11, 2007. KINAXO Biotechnologies GmbH announced today that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica N.V., Beerse, Belgium. Under the agreement, KINAXO will use the KinaTor™ technology to perform target selectivity analyses for selected J&JPRD small molecule compounds.
The KinaTor™ technology uses immobilized small molecule inhibitors to detect their protein binding partners in biological samples. Small molecule-protein interactions are identified by a combination of sophisticated affinity-based separation procedures and sensitive mass spectrometry. The KinaTor™ provides tailor-made solutions for various problems in drug development, such as the identification of previously unknown disease-relevant targets as well as off-target related toxicities.
About KINAXO
KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. We support pharmaceutical and biotechnology companies in their development and optimization of drugs.
As a spin-off of the Max-Planck Institute of Biochemistry in Martinsried, KINAXO offers extensive experience and a proven track record in cellular kinase profiling with several pharmaceutical and biotechnology company collaborations ongoing, i.e. UCB Pharma, Johnson & Johnson and Takeda. KINAXO is financed by European investors BioM, High-Tech Gründerfonds, KfW, Max Planck Society, and Mountain Partners.
>> back to Press Releases
>> download PDF (61 KB)